<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35949467</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1937-8688</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>The Pan African medical journal</Title><ISOAbbreviation>Pan Afr Med J</ISOAbbreviation></Journal><ArticleTitle>Curbing an outbreak of circulating vaccine derived poliovirus type 2 in Dollo Zone, Somali Region, Ethiopia: response to outbreak.</ArticleTitle><Pagination><StartPage>46</StartPage><MedlinePgn>46</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">46</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.11604/pamj.2022.42.46.32856</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">although the oral polio vaccine prevents virus transmission from person to person, it is crucial for poliovirus eradication. The continued use of live attenuated poliovirus poses an ongoing risk of circulating Vaccine Derived Poliovirus-2 (cVDPV2) outbreaks. This study assesses the response to the cVDPV2 outbreak in Dollo Zone, Somali Region, Ethiopia.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">after examining and verifying the occurrence of the outbreak, a team was established and prepared by resource mobilization, advocacy, and social mobilization. The group endorsed a four-step vaccination strategy, first the rapid response within 14-days by vaccinating a monovalent oral poliovirus-2 (mOPV2) to all under 5-year children in the Zone. The team further enhanced Supplementary Immunization Activities (SIA) for all under-five children with repeated doses of vaccines. At the same time, the team initiated community-based surveillance of Acute Flaccid Paralysis (AFP).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">in the rapid-response immunization, an average of 91.4% of 0-11 months old and 90.2% of 12-59 months children were vaccinated. In SIA-1, the team vaccinated an average of 88% and 97%, and in SIA-2, 94.8% and 97.6% of children 0-11 months old and 12-59 months old, respectively. The active community-based surveillance of AFP revealed the existence of the disease in a sporadic form, of which two cases were found in Bokh district.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">the response to curb the outbreak of cVDPV2 has shown a flow of actions to combat the outbreak. Strengthening and formation of response teams at different levels, resource mobilization, advocacy, and social mobilization are all essential components in maximizing the response to the outbreak.</AbstractText><CopyrightInformation>Copyright: Legesse Kidanne et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kidanne</LastName><ForeName>Legesse</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CORE Group Polio Project Secretariat, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bisrat</LastName><ForeName>Filimona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CORE Group Polio Project Secretariat, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Mohammud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Organization for Welfare and Development in Action, Jigjiga, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deyessa</LastName><ForeName>Negussie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Pan Afr Med J</MedlineTA><NlmUniqueID>101517926</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000629404">acute flaccid myelitis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020805" MajorTopicYN="N">Central Nervous System Viral Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005002" MajorTopicYN="N" Type="Geographic">Ethiopia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009187" MajorTopicYN="N">Myelitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009468" MajorTopicYN="N">Neuromuscular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012998" MajorTopicYN="N" Type="Geographic">Somalia</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Poliovirus</Keyword><Keyword MajorTopicYN="N">circulating vaccine</Keyword><Keyword MajorTopicYN="N">derived poliovirus</Keyword><Keyword MajorTopicYN="N">outbreak-response</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>11</Day><Hour>2</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35949467</ArticleId><ArticleId IdType="pmc">PMC9338724</ArticleId><ArticleId IdType="doi">10.11604/pamj.2022.42.46.32856</ArticleId><ArticleId IdType="pii">PAMJ-42-46</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groce NE, Banks LM, Stein MA. Surviving polio in a post-polio world. Soc Sci Med. 2014;107:171–178.</Citation><ArticleIdList><ArticleId IdType="pubmed">24607679</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ER, Moro PL, Cano M, Shimabukuro TT. Deaths following vaccination: what does the evidence show? Vaccine. 2015;33(29):3288–329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4599698</ArticleId><ArticleId IdType="pubmed">26004568</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi SJ, Sandhu HS, Venczel LV, Hymbaugh KJ, Deshpande JM, Pallansch MA, et al. Poliomyelitis-related case-fatality ratio in India, 2002-2006. Clin Infect Dis. 2011;53(1):13–19.</Citation><ArticleIdList><ArticleId IdType="pubmed">21653297</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlström G, Karlsson U. Disability and quality of life in individuals with postpolio syndrome. Disabil Rehabil. 2000;22(9):416–422.</Citation><ArticleIdList><ArticleId IdType="pubmed">10894205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12(6):1406–1417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4964727</ArticleId><ArticleId IdType="pubmed">27029786</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213–1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991634</ArticleId><ArticleId IdType="pubmed">20978089</ArticleId></ArticleIdList></Reference><Reference><Citation>Aylward B, Tangermann R. The global polio eradication initiative: lessons learned and prospects for success. Vaccine. 2011;29:D80–D85.</Citation><ArticleIdList><ArticleId IdType="pubmed">22486981</ArticleId></ArticleIdList></Reference><Reference><Citation>Leke RGF, King A, Pallansch MA, Tangermann RH, Mkanda P, Chunsuttiwat S, et al. Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world. Lancet Glob Health. 2020 Oct;8(10):e1345–e1351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525084</ArticleId><ArticleId IdType="pubmed">32916086</ArticleId></ArticleIdList></Reference><Reference><Citation>Adebisi YA, Prisno III, DE-L, Nuga BB. Last fight of wild polio in Africa: Nigeria´s battle. Public Health Pract (Oxf) 2020 Nov;1:100043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7528738</ArticleId><ArticleId IdType="pubmed">34173577</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales M, Tangermann RH, Wassilak SG. Progress toward polio eradication—worldwide, 2015-2016. Morbidity and mortality weekly report. 2016;65(18):470–473.</Citation><ArticleIdList><ArticleId IdType="pubmed">27171208</ArticleId></ArticleIdList></Reference><Reference><Citation>Angez M, Shaukat S, Alam MM, Sharif S, Khurshid A, Zaidi SSZ. Genetic relationships and epidemiological links between wild type 1 poliovirus isolates in Pakistan and Afghanistan. Virol J. 2012;9(1):1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307474</ArticleId><ArticleId IdType="pubmed">22353446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ. 2004 Jan;82(1):16–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585883</ArticleId><ArticleId IdType="pubmed">15106296</ArticleId></ArticleIdList></Reference><Reference><Citation>Diop OM, Asghar H, Gavrilin E, Moeletsi NG, Benito GR, Paladin F, et al. Virologic monitoring of poliovirus type 2 after oral poliovirus vaccine type 2 withdrawal in April 2016 worldwide, 2016-2017. MMWR Morbidity and mortality weekly report. 2017;66(20):538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657872</ArticleId><ArticleId IdType="pubmed">28542124</ArticleId></ArticleIdList></Reference><Reference><Citation>Initiative GPE: GPEI strategy for control of cVDPV2. 2020-2021</Citation></Reference><Reference><Citation>Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011;203(7):898–909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068031</ArticleId><ArticleId IdType="pubmed">21402542</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Jorba J, Greene SA, Diop OM, Iber J, Tallis G, et al. Update on vaccine-derived poliovirus outbreaks worldwide, July 2019-February 2020. Morbidity and Mortality Weekly Report. 2020;69(16):489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Persons IVIA, County WIDC, Virginia W. Update on Vaccine-Derived Poliovirus Outbreaks Worldwide July, 2019 February 2020. Notes 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Sufa D, Kerebih M, SheAbdi M, Belete H, Balalay V, al NBe. Somali Regional State. Ethiopia: In. Addis Ababa; 2019. Investigation Report of cVDPV2 Outbreak in Bokh Woreda of Dollo Zone.</Citation></Reference><Reference><Citation>Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol. 2003;13(5):277–291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12931339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sufa D, Gerema U. Investigation Report of cVDPV2 Outbreak in Bokh Woreda of Dollo Zone, Somali Regional State, Ethiopia. Case Rep Infect Dis. 2020 Aug 26;2020:6917313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471813</ArticleId><ArticleId IdType="pubmed">32908734</ArticleId></ArticleIdList></Reference><Reference><Citation>Sufa D, Kerebih M, SheAbdi M, Belete H, Balalay V. In Edited by report D. 2019. al NBe: cVDPV Outbreak Investigation Report, Bokh Woreda, Dollo Zone, Somali Region, Ethiopia.</Citation></Reference><Reference><Citation>In Edited by Immunization EPo. Geneva: 1991. World Health Organization: Responding to A suspected Polio Outbreak: Case Investigationm Surveillance and Control; A Manager's Checklist.</Citation></Reference><Reference><Citation>Organization WH. 2020. Standard operating procedures: responding to a poliovirus event or outbreak.</Citation></Reference><Reference><Citation>World Health Organization Geneva The global epidemiology of infectious diseases. Accessed on 15th December, 2021.</Citation></Reference><Reference><Citation>Carvalho AF. Advocacy for Stronger Immunization Programs. Vaccinology. 2018. p. 249.</Citation></Reference><Reference><Citation>Flores A, Villeda JA, Rodríguez-Fernández R, Chévez AE, Barrera L, Tezaguic R, et al. Advocacy and resource mobilization for rubella elimination in Guatemala. J Infect Dis. 2011;204(suppl_2):S598–S602.</Citation><ArticleIdList><ArticleId IdType="pubmed">21954253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns W, Smith S, Small R, Dunkerley R, Green D. Herd immunity to poliovirus in Dundee. Health Bull (Edinb) 1982;40(6):296–305.</Citation><ArticleIdList><ArticleId IdType="pubmed">6298147</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>